PROGRESSIVE CARDIAC AMYLOIDOSIS FOLLOWING L AMYLOID POLYNEUROPATHY

Transplantation

66, 229-233

DOI: 10.1097/00007890-199807270-00016

Citation Report

#	Article	IF	Citations
1	Cardiac evaluation of patients with familial amyloidotic polyneuropathy proposed for liver transplantation. Transplantation Proceedings, 1999, 31, 2372.	0.3	3
2	Musical Hallucinations After Living-Donor Liver Transplantation. Psychosomatics, 1999, 40, 530-531.	2.5	9
3	Liver transplantation for hereditary transthyretin amyloidosis. Liver Transplantation, 2000, 6, 263-276.	1.3	123
4	Sequential (domino) transplantation of the liver in a transthyretin-50 familial amyloid polyneuropathy. Langenbeck's Archives of Surgery, 2000, 385, 21-26.	0.8	14
5	Heart failure caused by a novel amyloidogenic mutation of the transthyretin gene: ATTR Ala45Ser. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2000, 7, 137-140.	1.4	17
6	Cardiac Amyloid in Patients with Familial Amyloid Polyneuropathy Consists of Abundant Wild-Type Transthyretin. Biochemical and Biophysical Research Communications, 2000, 274, 702-706.	1.0	155
7	An Italian family with Ala-47 transthyretin mutation associated with cardiomyopathy and polyneuropathy. Neuromuscular Disorders, 2000, 10, 52-55.	0.3	6
8	Remission of proteinuria following liver transplantation for familial amyloid polyneuropathy TTR Met30. Transplantation Proceedings, 2000, 32, 2664-2666.	0.3	14
9	Suppression of transthyretin expression by ribozymes: a possible therapy for familial amyloidotic polyneuropathy. Journal of the Neurological Sciences, 2001, 183, 79-84.	0.3	34
10	Cautions after Liver Transplantation for Familial Amyloidotic Polyneuropathy. Internal Medicine, 2001, 40, 193-194.	0.3	0
11	Combined heart and liver transplantation for familial amyloidosis. Internal Medicine Journal, 2001, 31, 66-67.	0.5	19
12	Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Human Mutation, 2001, 17, 493-503.	1.1	200
13	Long term results of heart transplantation in patients with amyloid heart disease. British Heart Journal, 2001, 85, 202-207.	2.2	91
14	Transthyretin-associated neuropathic amyloidosis. Neurology, 2001, 56, 431-435.	1.5	113
15	Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 108-114.	1.4	141
16	Familial transthyretin-type amyloid polyneuropathy in Japan. Neurology, 2002, 58, 1001-1007.	1.5	204
17	Induction of Protein Conformational Change in Mouse Senile Amyloidosis. Journal of Biological Chemistry, 2002, 277, 33164-33169.	1.6	48
18	Transthyretin mutation (TTRGly47Ala) associated with familial amyloid polyneuropathy in a French family. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 272-275.	1.4	5

#	Article	IF	Citations
19	Long-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type). Liver Transplantation, 2002, 8, 787-794.	1.3	76
20	Combined heart and liver transplantation for familial amyloidotic neuropathy: Considerations from the hepatic point of view. Liver Transplantation, 2003, 9, 986-992.	1.3	46
21	Gastrointestinal amyloidosis: Approach to treatment. Current Treatment Options in Gastroenterology, 2003, 6, 17-25.	0.3	16
22	Combined heart and liver transplantation for familial amyloidotic polyneuropathy. Journal of Thoracic and Cardiovascular Surgery, 2003, 125, 1165-1166.	0.4	33
23	Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid. Muscle and Nerve, 2003, 28, 438-442.	1.0	48
24	Outcome of liver transplantation for familial amyloidotic polyneuropathy. Liver Transplantation, 2003, 9, 1273-1280.	1.3	46
25	Hereditary transthyretin amyloidosis from a Scandinavian perspective. Journal of Internal Medicine, 2003, 254, 225-235.	2.7	91
26	Caso clÃnico PolineuropatÃa en un paciente con ingesta excesiva de alcohol. Medicine, 2003, 8, 5417-5418.	0.0	0
27	Liver transplantation as treatment for neurological disorders. Expert Review of Neurotherapeutics, 2003, 3, 547-555.	1.4	6
28	Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 229-239.	1.4	41
29	Orthotopic liver transplantation for hereditary fibrinogen amyloidosis. Transplantation, 2003, 75, 560-561.	0.5	53
30	Clinical and pathological findings of non-Val30Met TTR type familial amyloid polyneuropathy in Japan. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 39-47.	1.4	12
31	Report from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR) and the Domino Liver Transplant Registry (DLTR). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 67-76.	1.4	138
32	Impact of liver transplantation on familial amyloidotic polyneuropathy (FAP) patients' symptoms and complications. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 77-83.	1.4	37
33	Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers. Laboratory Investigation, 2004, 84, 865-873.	1.7	64
34	Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Reviews, 2004, 18, 17-37.	2.8	59
36	Metabolic storage diseases: amyloidosis. Clinics in Liver Disease, 2004, 8, 915-930.	1.0	17
37	Cardiomyopathies restrictives. EMC - Cardiologie-Angeiologie, 2004, 1, 256-270.	0.9	0

#	Article	IF	Citations
38	Combined heart and liver transplantation in four adults with familial amyloidosis: experience of a single center. Transplantation Proceedings, 2004, 36, 645-647.	0.3	54
39	Familial amyloid polyneuropathy and liver transplantation. Journal of Hepatology, 2004, 41, 188-194.	1.8	39
40	Cardiac transplantation for amyloid heart disease: The United Kingdom experience. Journal of Heart and Lung Transplantation, 2004, 23, 1142-1153.	0.3	165
41	Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Current Opinion in Neurology, 2004, 17, 615-620.	1.8	98
42	Liver Transplantation Does Not Prevent the Development of Life-Threatening Arrhythmia in Familial Amyloidotic Polyneuropathy, Portuguese-Type (ATTR Val30Met) Patients. Transplantation, 2004, 78, 112-116.	0.5	76
43	The systemic amyloidoses. Current Opinion in Rheumatology, 2004, 16, 67-75.	2.0	118
44	Cardiac Amyloidosis: Heterogenous Pathogenic Backgrounds. Internal Medicine, 2004, 43, 1107-1114.	0.3	26
45	Ten Years of Experience with Liver Transplantation for Familial Amyloid Polyneuropathy in Japan: Outcomes of Living Donor Liver Transplantations. Internal Medicine, 2005, 44, 1151-1156.	0.3	45
46	Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation, 2005, 111, 186-193.	1.6	863
47	Early liver transplantation improves familial amyloidotic polyneuropathy patients' survival. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 233-238.	1.4	62
48	A Swedish family with the rare Phe33Leu transthyretin mutation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 189-192.	1.4	8
49	Diagnosis and Management of the Cardiac Amyloidoses. Circulation, 2005, 112, 2047-2060.	1.6	696
50	Liver Transplantation for Familial Amyloid Polyneuropathy Non-VAL30MET Variants: Are Cardiac Complications Influenced by Prophylactic Pacing and Immunosuppressive Weaning?. Transplantation Proceedings, 2005, 37, 2214-2220.	0.3	7
51	Cardiomyopathy in Swedish patients with the Gly53Glu and His88Arg transthyretin variants. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 184-188.	1.4	18
52	Amyloidosis. Annual Review of Medicine, 2006, 57, 223-241.	5.0	557
54	Effect of tacrolimus and partial hepatectomy on transthyretin metabolism in rats. Transplant International, 2006, 19, 233-238.	0.8	5
55	Successful Hepatorenal Transplantation in Hereditary Amyloidosis Caused by a Frame-Shift Mutation in Fibrinogen AÎ±-Chain Gene. American Journal of Transplantation, 2006, 6, 632-635.	2.6	32
56	Ventricular late potentials in familial amyloidotic polyneuropathy. Journal of Electrocardiology, 2006, 39, 57-62.	0.4	12

#	Article	IF	Citations
57	Severe congestive heart failure with cardiac liver cirrhosis 10 years after orthotopic liver transplantation for familial amyloidotic polyneuropathy. Pathology International, 2006, 56, 408-412.	0.6	14
58	Impact of Liver Transplantation on Cardiac Autonomic Denervation in Familial Amyloid Polyneuropathy. Medicine (United States), 2006, 85, 229-238.	0.4	63
59	Aging and transthyretin-related amyloidosis: Pathologic examinations in pulmonary amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2006, 13, 24-30.	1.4	31
60	Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: Towards tailoring of therapeutic strategies?. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2006, 13, 143-153.	1.4	57
61	Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2006, 13, 154-159.	1.4	50
62	Chapter 21 Amyloidosis. Handbook of Systemic Autoimmune Diseases, 2007, 7, 383-396.	0.1	1
63	A new transthyretin variant (Glu61Gly) associated with cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 65-71.	1.4	9
64	Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 277-282.	1.4	110
65	Combined heart and liver transplantation for familial amyloidotic neuropathy. European Journal of Cardio-thoracic Surgery, 2007, 32, 180-182.	0.6	49
66	Cardiac Transplantation Using Extended-Donor Criteria Organs for Systemic Amyloidosis Complicated by Heart Failure. Transplantation, 2007, 83, 539-545.	0.5	73
67	Combined Cardiac and Liver Transplantation for the Treatment of Familial Amyloidosis. Baylor University Medical Center Proceedings, 2007, 20, 146-148.	0.2	2
68	The molecular biology and clinical features of amyloid neuropathy. Muscle and Nerve, 2007, 36, 411-423.	1.0	449
69	Familial amyloidosis in a large Spanish kindred resulting from a D38V mutation in the transthyretin gene. European Journal of Clinical Investigation, 2007, 37, 673-678.	1.7	1
70	Progressive Wild-Type Transthyretin Deposition after Liver Transplantation Preferentially Occurs onto Myocardium in FAP Patients. American Journal of Transplantation, 2007, 7, 235-242.	2.6	110
71	An Unusual Case of Cardiac Amyloidosis. Journal of General Internal Medicine, 2007, 22, 1047-1052.	1.3	6
72	Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. Journal of Pathology, 2008, 216, 253-261.	2.1	171
73	Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation. Liver Transplantation, 2008, 14, 563-570.	1.3	62
74	Do troponin and Bâ€natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis?. Journal of Internal Medicine, 2008, 263, 294-301.	2.7	53

#	Article	IF	Citations
75	Accelerating restrictive cardiomyopathy after liver transplantation in a patient with familial amyloidotic polyneuropathy: a case report. Journal of Medical Case Reports, 2008, 2, 35.	0.4	5
76	Current State of Combined Heartâ€“Liver Transplantation in the United States. Journal of Heart and Lung Transplantation, 2008, 27, 753-759.	0.3	83
77	A Case of Polyneuropathy and Proteinuria. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 624-636.	2.2	8
78	Evaluation of Myocardial Changes in Familial Amyloid Polyneuropathy after Liver Transplantation. Internal Medicine, 2008, 47, 2133-2137.	0.3	29
79	Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 63-70.	1.4	50
80	Chain reaction of amyloid fibril formation with induction of basement membrane in familial amyloidotic polyneuropathy. Journal of Pathology, 2009, 219, 481-490.	2.1	37
81	Proportion between wild-type and mutant protein in truncated compared to full-length ATTR: An analysis on transplanted transthyretin T60A amyloidosis patients. Biochemical and Biophysical Research Communications, 2009, 379, 846-850.	1.0	24
82	Combined Heart and Liver Transplantation: A Single-Center Experience. Transplantation, 2009, 88, 219-225.	0.5	118
83	Amyloid Heart Disease. Progress in Cardiovascular Diseases, 2010, 52, 347-361.	1.6	202
85	Poor outcome after liver transplantation for transthyretin amyloid neuropathy in a family with an Ala36Pro transthyretin mutation: Case Report. Liver Transplantation, 2010, 16, NA-NA.	1.3	4
86	Effect of recipient-derived cells on the progression of familial amyloidotic polyneuropathy after liver transplantation: a retrospective study. Annals of Clinical Biochemistry, 2010, 47, 529-534.	0.8	1
87	Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology, 2010, 75, 324-327.	1.5	136
89	Heart complications in familial transthyretin amyloidosis: impact of age and gender. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2010, 17, 63-68.	1.4	72
90	Prognostic value of pre-transplant cardiomyopathy in Swedish liver transplanted patients for familial amyloidotic polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 171-173.	1.4	12
91	The diflunisal trial: update on study drug tolerance and disease progression. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 196-197.	1.4	20
92	Cardiac Amyloidosis: A Practical Approach to Diagnosis and Management. American Journal of Medicine, 2011, 124, 1006-1015.	0.6	97
93	Wild-type transthyretin significantly contributes to the formation of amyloid fibrils in familial amyloid polyneuropathy patients with amyloidogenic transthyretin Val30Met. Human Pathology, 2011, 42, 236-243.	1.1	20
94	Pre operative cardio pulmonary assessment of the liver transplant candidate. Annals of Hepatology, 2011, 10, 421-433.	0.6	14

#	Article	IF	Citations
95	Successful Heart and Liver Transplantation in a Swiss Patient With Glu89Lys Transthyretin Amyloidosis. Transplantation, 2011, 91, e40-e42.	0.5	4
97	Manifestations of transthyretin-related familial amyloidotic polyneuropathy: Long-term follow-up of Japanese patients after liver transplantation. Surgery Today, 2011, 41, 1211-1218.	0.7	41
98	Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis. Journal of Molecular Medicine, 2011, 89, 171-180.	1.7	74
99	Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 200-205.	1.4	57
100	Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 193-195.	1.4	81
102	New insights into the clinical evaluation of hereditary transthyretin amyloidosis patients: a single center's experience. Degenerative Neurological and Neuromuscular Disease, 2012, 2, 93.	0.7	1
103	Amyloid Fibril Composition as a Predictor of Development of Cardiomyopathy After Liver Transplantation for Hereditary Transthyretin Amyloidosis. Transplantation, 2012, 93, 1017-1023.	0.5	52
104	Neuropatie amiloidi familiari. EMC - Neurologia, 2012, 12, 1-12.	0.0	0
105	Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. European Heart Journal, 2012, 33, 1120-1127.	1.0	143
106	The Diflunisal Trial: Study accrual and drug tolerance. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 37-38.	1.4	39
107	Amyloid diseases of the heart: current and future therapies. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 617-631.	0.2	22
108	Transthyretin familial amyloid polyneuropathy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 115, 643-658.	1.0	42
109	Systemic amyloidoses: What an internist should know. European Journal of Internal Medicine, 2013, 24, 729-739.	1.0	31
110	Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. Journal of Neurology, 2013, 260, 2802-2814.	1.8	284
111	Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis. Journal of Cardiovascular Translational Research, 2013, 6, 1011-1020.	1.1	122
112	Liver transplantation and transthyretin amyloidosis. Muscle and Nerve, 2013, 47, 157-162.	1.0	92
113	Cardiac amyloidosis: A comprehensive review. Cor Et Vasa, 2013, 55, e60-e75.	0.1	38
114	Treatment of End Stage Heart Failure Related to Cardiac Amyloidosis. , 2013, , .		0

#	Article	IF	Citations
115	Steady turnover of amyloid fibril proteins in gastric mucosa after liver transplantation in familial amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 156-163.	1.4	10
116	RETINAL MICROANGIOPATHY AS AN INITIAL MANIFESTATION OF FAMILIAL AMYLOID CARDIOMYOPATHY ASSOCIATED WITH TRANSTHYRETIN E89K MUTATION. Retinal Cases and Brief Reports, 2013, 7, 271-275.	0.3	6
117	Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica, 2014, 99, 1239-1247.	1.7	140
118	Recent progress in the understanding and treatment of transthyretin amyloidosis. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 225-233.	0.7	57
119	Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet Journal of Rare Diseases, 2015, 10, 109.	1.2	246
120	Outcome in patients treated with isolated liver transplantation for familial transthyretin amyloidosis to prevent cardiomyopathy. Clinical Transplantation, 2015, 29, 1098-1104.	0.8	6
121	Liver Transplantation for Hereditary Transthyretin Amyloidosis. Transplantation, 2015, 99, 1847-1854.	0.5	257
122	The transthyretin amyloidoses: advances in therapy. Postgraduate Medical Journal, 2015, 91, 439-448.	0.9	33
123	Cardiac amyloidosis: where are we today?. Journal of Internal Medicine, 2015, 278, 126-144.	2.7	61
124	Evolving landscape in the management of transthyretin amyloidosis. Annals of Medicine, 2015, 47, 625-638.	1.5	181
125	Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis. Journal of Cardiovascular Translational Research, 2015, 8, 117-127.	1.1	61
126	Bifunctional crosslinking ligands for transthyretin. Open Biology, 2015, 5, 150105.	1.5	2
127	Novel strategies for the diagnosis and treatment of cardiac amyloidosis. Expert Review of Cardiovascular Therapy, 2015, 13, 1195-1211.	0.6	29
128	Current and future treatment of amyloid diseases. Journal of Internal Medicine, 2016, 280, 177-202.	2.7	73
129	Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox?. Annals of Neurology, 2016, 80, 401-411.	2.8	17
130	^{99m}Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Upsala Journal of Medical Sciences, 2016, 121, 17-24.	0.4	82
131	Survival After Transplantation in Patients With Mutations Other Than Val30Met. Transplantation, 2016, 100, 373-381.	0.5	65
132	Systemic amyloidosis. Lancet, The, 2016, 387, 2641-2654.	6.3	703

#	Article	IF	Citations
133	One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. Journal of Internal Medicine, 2017, 281, 337-347.	2.7	94
134	Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy. Clinical Science, 2017, 131, 395-409.	1.8	66
135	ProgressÃ£o da desnervaÃ§Ã£o simpÃ¡tica cardÃaca avaliada por cintigrafia com MIBGâ€I123 na polineuropatia amiloidÃ³tica familiar e o impacto da transplantaÃ§Ã£o hepÃ¡tica. Revista Portuguesa De Cardiologia, 2017, 36, 333-340.	0.2	15
136	Progression of myocardial sympathetic denervation assessed by 123I-MIBG imaging in familial amyloid polyneuropathy and the effect of liver transplantation. Revista Portuguesa De Cardiologia (English) Tj ETQq1 1 0.784314 rgBT /Overlock	0.3	11
137	Acquired transthyretin amyloidosis after domino liver transplant: Phenotypic correlation, implication of liver retransplantation. Journal of the Neurological Sciences, 2017, 379, 192-197.	0.3	9
138	Cardiac Amyloidosis: An Updated Review With Emphasis on Diagnosis and Future Directions. Current Problems in Cardiology, 2018, 43, 10-34.	1.1	74
139	Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy. Arquivos De Neuro-Psiquiatria, 2018, 76, 609-621.	0.3	16
140	Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6741-E6750.	3.3	66
141	History and Current Status of Cardiac Anesthesia in Singapore. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 3394-3401.	0.6	5
142	Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Diseases. International Journal of Molecular Sciences, 2019, 20, 2982.	1.8	20
143	Systemic Amyloidosis. , 2019, , 267-289.		1
144	A molecular mechanism for transthyretin amyloidogenesis. Nature Communications, 2019, 10, 925.	5.8	92
145	Tafamidis for the treatment of transthyretin amyloidosis. Future Cardiology, 2019, 15, 53-61.	0.5	3
147	Pearls and Oy-sters: Number, weaker, and dizzier due to transthyretin amyloidosis after two liver transplants. Neurology, 2020, 96, 10.1212/WNL.0000000000011289.	1.5	1
148	Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story. Drug Design, Development and Therapy, 2021, Volume 15, 1225-1243.	2.0	29
149	Amyloid Heart Disease. , 2010, , 107-128.		5
150	Liver Transplantation for Transthyretin Amyloidosis. , 2009, , 239-260.		2
151	Hereditary Amyloid Neuropathy. , 2005, , 1921-1935.		5

#	Article	IF	Citations
152	Disorders of Peripheral Nerves. , 2008, , 2249-2355.		18
153	Disorders of Peripheral Nerves. , 2012, , 1915-2015.		11
154	Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, portuguese type1. Transplantation, 2002, 73, 745-751.	0.5	139
155	Hereditary Amyloidosis with Recurrent Lung Infiltrates. American Journal of Case Reports, 2016, 17, 874-879.	0.3	3
156	Contemporary Treatment of Amyloid Heart Disease. Current Pharmaceutical Design, 2014, 21, 491-506.	0.9	7
158	Cardiovascular Involvement in Transthyretin Cardiac Amyloidosis. Heart Failure Clinics, 2022, 18, 73-87.	1.0	12
159	Immunoglobulin Light Chain Amyloidosis (Primary Amyloidosis, AL). , 2004, , 157-195.		1
160	Continued Deposition of Wild-Type Transthyretin in Cardiac Amyloid after Liver Transplantation. , 2004, , 354-356.		1
161	Effect of Tacrolimus and Cyclosporine on Transthyretin (Ttr) Metabolism in Rats. , 2007, , 214-216.		0
163	ATTR: Diagnosis, Prognosis, and Treatment. , 2010, , 191-204.		3
164	Hereditary Neuromuscular Diseases and Cardiac Involvement. , 2011, , 385-400.		0
165	Cardiac and Multi-Organ Transplantation in Patients with Amyloidosis. , 0, , .		0
166	Clinical and Pathologic Issues in Patients with Amyloidosis: Practical Comments Regarding Diagnosis, Therapy, and Solid Organ Transplantation. , 2012, , 377-391.		0
167	Peripheral Nerve Amyloidosis. , 2012, , 361-374.		1
169	Clinical and Pathologic Issues in Patients with Amyloidosis: Summary and Practical Comments Regarding Diagnosis, Therapy, and Solid Organ Transplantation. Current Clinical Pathology, 2015, , 489-505.	0.0	1
170	Peripheral Nerve Amyloidosis. Current Clinical Pathology, 2015, , 437-450.	0.0	1
171	Hereditary Neuromuscular Diseases and Cardiac Involvement. , 2016, , 373-388.		0
173	CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. New England Journal of Medicine, 2021, 385, 1721-1723.	13.9	13

#	Article	IF	Citations
174	Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management. Texas Heart Institute Journal, 2005, 32, 178-84.	0.1	73
175	Hipertrofia Ventricular Esquerda: Um FenÃ³tipo, Duas HipÃ³teses, TrÃªs LiÃ§Ãµes. Arquivos Brasileiros De Cardiologia, 2021, 117, 1056-1059.	0.3	0
176	Development of amyloid beta gold nanorod aggregates as optoacoustic probes. PLoS ONE, 2022, 17, e0259608.	1.1	1
177	Amyloid neuropathy and autonomic dysfunction. Neurology and Clinical Neuroscience, 0, , .	0.2	3
178	High-avidity binding drives nucleation of amyloidogenic transthyretin monomer. JCI Insight, 2022, 7, .	2.3	2
179	Molecular Mechanisms of Cardiac Amyloidosis. International Journal of Molecular Sciences, 2022, 23, 25.	1.8	20
180	Analysis of amyloidogenic transthyretin mutations using continuum solvent free energy calculations. Proteins: Structure, Function and Bioinformatics, 2022, 90, 2080-2090.	1.5	2
181	Protein Aggregation in Neurodegenerative Diseases. , 2022, , 26-58.		0
182	A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives. European Journal of Medicinal Chemistry, 2022, 243, 114742.	2.6	1
183	Tissue-based diagnosis of systemic amyloidosis: Experience of the informal diagnostic center at Uppsala University Hospital. Upsala Journal of Medical Sciences, 0, 127, .	0.4	1